TY - JOUR
T1 - Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas
AU - Dao, Long
AU - Ragoonanan, Dristhi
AU - Batth, Izhar
AU - Satelli, Arun
AU - Foglesong, Jessica
AU - Wang, Jian
AU - Zaky, Wafik
AU - Gill, Jonathan B.
AU - Liu, Diane
AU - Albert, Aisha
AU - Gordon, Nancy
AU - Huh, Winston
AU - Harrison, Douglas
AU - Herzog, Cynthia
AU - Kleinerman, Eugenie
AU - Gorlick, Richard
AU - Daw, Najat
AU - Li, Shulin
N1 - Funding Information:
This study was funded by the NIH Grant R01 EB026291. The NIH had no role in the design and conduct of this study.
Publisher Copyright:
Copyright © 2021 Dao, Ragoonanan, Batth, Satelli, Foglesong, Wang, Zaky, Gill, Liu, Albert, Gordon, Huh, Harrison, Herzog, Kleinerman, Gorlick, Daw and Li.
PY - 2021/12/9
Y1 - 2021/12/9
N2 - Background: Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains reliant on serial imaging which increases the risk of secondary malignancies and heightens patient anxiety. Methods: Here, for the first time reported in the literature, we have enumerated the cell surface vimentin (CSV+) CTCs in the blood of 92 sarcoma pediatric and adolescent and young adult (AYA) patients as a possible marker of disease. Results: We constructed a ROC with an AUC of 0.831 resulting in a sensitivity of 85.3% and a specificity of 75%. Additionally, patients who were deemed to be CSV+ CTC positive were found to have a worse overall survival compared to those who were CSV+ CTC negative. We additionally found the use of available molecular testing increased the accuracy of our diagnostic and prognostic tests. Conclusions: Our findings indicate that CSV+ CTCs have prognostic value and can possibly serve as a measure of disease burden.
AB - Background: Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains reliant on serial imaging which increases the risk of secondary malignancies and heightens patient anxiety. Methods: Here, for the first time reported in the literature, we have enumerated the cell surface vimentin (CSV+) CTCs in the blood of 92 sarcoma pediatric and adolescent and young adult (AYA) patients as a possible marker of disease. Results: We constructed a ROC with an AUC of 0.831 resulting in a sensitivity of 85.3% and a specificity of 75%. Additionally, patients who were deemed to be CSV+ CTC positive were found to have a worse overall survival compared to those who were CSV+ CTC negative. We additionally found the use of available molecular testing increased the accuracy of our diagnostic and prognostic tests. Conclusions: Our findings indicate that CSV+ CTCs have prognostic value and can possibly serve as a measure of disease burden.
KW - adult and young adolescent (AYA)
KW - area under curve (AUC)
KW - cell surface vimentin (CSV)
KW - circulating tumor cell (CTC)
KW - clinical laboratory improvement amendments (CLIA)
KW - epithelial cellular adhesion molecule (EpCAM)
KW - receiver operating characteristic curve (ROC)
UR - http://www.scopus.com/inward/record.url?scp=85121614852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121614852&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.760267
DO - 10.3389/fonc.2021.760267
M3 - Article
C2 - 34956881
AN - SCOPUS:85121614852
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 760267
ER -
